Snowdon Inc. is a pharmaceutical company that is focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines.
Snowdon’s pipeline extends from NCEs to repurposing off-patent drugs for new clinical indications. The company’s preclinical lead compound, SND-121, has shown exceptional safety and efficacy when administered orally in rodent models as a treatment for neuropathic pain. SND-121 appears to treat pain through a unique mechanism of action, distinct from traditional analgesics such as opioid narcotics, NSAIDs, or the antiepileptics gabapentin and pregabalin.
In the infectious disease arena, Snowdon is engaged in discovery-stage projects on SND-159 for tuberculosis and SND-226 for toxoplasmosis. The toxoplasmosis project has been funded through grants from the NIH and the New Jersey Commission on Science & Technology (NJCST). More recently, Snowdon was awarded a three-year $8.2 million contract by the Defense Threat Reduction Agency-Transformational Medical Technologies (DTRA-TMT) of the Department of Defense (DoD) to develop novel medical treatments for combating biowarfare pathogens.
Snowdon is also pursuing early stage discovery projects aimed at novel medical treatments for neurological disorders, such as Fragile X Syndrome (FXS) which is the most common known cause of autism and autistic-like behaviors.
Snowdon's Drug Discovery Platform. Snowdon’s technology platform E-Prospector is built for speed, economy, and maximum success rate. E-Prospector enables our scientists to rapidly identify high-value molecules from an in-house computer library of vendor-available compounds, which can then be purchased in small quantities for initial biological evaluation. Additional computational filters predict whether selected molecules satisfy key requirements, including high binding affinity for the intended target, acceptable ADME profile, low toxicity, and synthetic accessibility. Our approach enables rapid progression from “hit” to “lead” in the drug discovery process, and allows us to focus only on the most promising drug leads. The more cost- and time-consuming steps of structural optimization via medicinal organic chemistry and biological evaluation are reserved exclusively for the most promising drug prospects. With an existing pipeline of preclinical drug candidates fed by an advanced technology platform, Snowdon possesses the core capabilities to deliver breakthrough pharmaceutical products for the marketplace and for the patient.
Computational Tools for Assessing Product Quality and Safety. Snowdon’s expertise extends to the critical areas of product quality and safety, through the development and application of advanced computational tools in statistics, pattern recognition, multivariate chemometrics analysis, and artificial intelligence. Global concern about product quality and safety has risen lately due to the well publicized tragic incidences of deliberately contaminated heparin in 2008 and melamine-contaminated milk and pet food in 2007. In response to these international crises, Snowdon has partnered with industry and government organizations in finding solutions to diverse problems ranging from food, pharmaceuticals, and personal care products to environmental science, biodefense, and chemical manufacturing. Beyond their utility for real-time monitoring and quality control of pharmaceutical manufacturing processes, Snowdon’s approaches apply equally well to pinpointing suspect products, such as substandard, adulterated, contaminated, or counterfeit samples.